{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T20:00:43Z","timestamp":1765742443658,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41391-018-0047-8","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T09:23:45Z","timestamp":1527845025000},"page":"277-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study"],"prefix":"10.1038","volume":"21","author":[{"given":"Wei-Ming","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Pasaribu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gau-Tyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-2673","authenticated-orcid":false,"given":"Hung-Pin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"47_CR1","first-page":"S75","volume":"179","author":"JT Wei","year":"2008","unstructured":"Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia. J Urol. 2008;179:S75\u201380.","journal-title":"J Urol"},{"key":"47_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","volume":"361","author":"A Thorpe","year":"2003","unstructured":"Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359\u201367.","journal-title":"Lancet"},{"key":"47_CR3","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","volume":"7","author":"SWH Lee","year":"2017","unstructured":"Lee SWH,Chan EMC,Lai YK, The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7:7984.","journal-title":"Sci Rep"},{"key":"47_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3949\/ccjm.84a.16008","volume":"84","author":"R Unnikrishnan","year":"2017","unstructured":"Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: evaluation and medical management in primary care. Cleve Clin J Med. 2017;84:53\u201364.","journal-title":"Cleve Clin J Med"},{"key":"47_CR5","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20138. Arthritis Rheum. 2011;63:3136\u201341.","journal-title":"Arthritis Rheum"},{"key":"47_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","volume":"17","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Zhang W, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13.","journal-title":"Arthritis Res Ther"},{"key":"47_CR7","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039\u201352.","journal-title":"Lancet"},{"key":"47_CR8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765\u201370.","journal-title":"Ann Rheum Dis"},{"key":"47_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642\u201350.","journal-title":"Am J Kidney Dis"},{"key":"47_CR10","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"CW Tsai","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE. 2017;12:e0170393.","journal-title":"PLoS ONE"},{"key":"47_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1607-551X(09)70412-7","volume":"23","author":"YH Chou","year":"2007","unstructured":"Chou YH, Li WM, Li CC, Huang SP, Liu CC, Wu WJ, et al. Clinical study of uric acid urolithiasis. Kaohsiung J Med Sci. 2007;23:298\u2013301.","journal-title":"Kaohsiung J Med Sci"},{"key":"47_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000176025","volume":"82","author":"WM Li","year":"2009","unstructured":"Li WM, Chou YH, Li CC, Liu CC, Huang SP, Wu WJ, et al. Local factors compared with systemic factors in the formation of bladder uric acid stones. Urol Int. 2009;82:48\u201352.","journal-title":"Urol Int"},{"key":"47_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.2990230203","volume":"23","author":"S Holmang","year":"1993","unstructured":"Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23:99\u2013106.","journal-title":"Prostate"},{"key":"47_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/pros.23365","volume":"77","author":"T Pejcic","year":"2017","unstructured":"Pejcic T, Tosti T, Tesic Z, Milkovic B, Dragicevic D, Kozomara M, et al. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume. Prostate. 2017;77:1082\u201392.","journal-title":"Prostate"},{"key":"47_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/rheumatology\/ken391","volume":"47","author":"K Pui","year":"2008","unstructured":"Pui K, Waddell C, Dalbeth N. Early onset of hyperuricaemia and gout following treatment for female to male gender reassignment. Rheumatology. 2008;47:1840\u20131.","journal-title":"Rheumatology"},{"key":"47_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/art.1780280203","volume":"28","author":"E Marinello","year":"1985","unstructured":"Marinello E, Riario-Sforza G, Marcolongo R. Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout. Arthritis Rheum. 1985;28:127\u201331.","journal-title":"Arthritis Rheum"},{"key":"47_CR17","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"47_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrurol.2015.301","volume":"13","author":"L Vignozzi","year":"2016","unstructured":"Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108\u201319.","journal-title":"Nat Rev Urol"},{"key":"47_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/pros.23451","volume":"78","author":"HJ Shih","year":"2018","unstructured":"Shih HJ, Huang CJ, Lin JA, Kao MC, Fan YC, Tsai PS. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. Prostate. 2018;78:113\u201320.","journal-title":"Prostate"},{"key":"47_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/ard.57.9.509","volume":"57","author":"B Emmerson","year":"1998","unstructured":"Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509\u201310.","journal-title":"Ann Rheum Dis"},{"key":"47_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM. American college of P, American Physiological S. Pathogenesis of gout. Ann Intern Med. 2005;143:499\u2013516.","journal-title":"Ann Intern Med"},{"key":"47_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10:654\u201361.","journal-title":"Nat Rev Rheumatol"},{"key":"47_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20138. Am J Med. 2012;125:679\u201387 e671.","journal-title":"Am J Med"},{"key":"47_CR24","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.ajkd.2016.11.006","volume":"69","author":"MA Lusco","year":"2017","unstructured":"Lusco MA, Fogo AB, Najafian B, Alpers CE. AJKD atlas of renal pathology: gouty nephropathy. Am J Kidney Dis. 2017;69:e5\u20136.","journal-title":"Am J Kidney Dis"},{"key":"47_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jare.2017.04.005","volume":"8","author":"A Abou-Elela","year":"2017","unstructured":"Abou-Elela A. Epidemiology, pathophysiology, and management of uric acid urolithiasis: a narrative review. J Adv Res. 2017;8:513\u201327.","journal-title":"J Adv Res"},{"key":"47_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11010-016-2671-8","volume":"414","author":"F Sangkop","year":"2016","unstructured":"Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem. 2016;414:187\u201399.","journal-title":"Mol Cell Biochem"},{"key":"47_CR27","doi-asserted-by":"publisher","first-page":"183041","DOI":"10.1155\/2013\/183041","volume":"2013","author":"S Vodo","year":"2013","unstructured":"Vodo S, Bechi N, Petroni A, Muscoli C, Aloisi AM. Testosterone-induced effects on lipids and inflammation. Mediat Inflamm. 2013;2013:183041.","journal-title":"Mediat Inflamm"},{"key":"47_CR28","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/JOE-12-0582","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217:R47\u201371.","journal-title":"J Endocrinol"},{"key":"47_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1034\/j.1399-302X.2002.170309.x","volume":"17","author":"RD Coletta","year":"2002","unstructured":"Coletta RD, Reynolds MA, Martelli-Junior H, Graner E, Almeida OP, Sauk JJ. Testosterone stimulates proliferation and inhibits interleukin-6 production of normal and hereditary gingival fibromatosis fibroblasts. Oral Microbiol Immunol. 2002;17:186\u201392.","journal-title":"Oral Microbiol Immunol"},{"key":"47_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/jc.2015-3611","volume":"101","author":"J Veldhuis","year":"2016","unstructured":"Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory cytokine infusion attenuates LH\u2019s feedforward on testosterone secretion: modulation by age. J Clin Endocrinol Metab. 2016;101:539\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"47_CR31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1507\/endocrj.EJ13-0203","volume":"60","author":"H Kurahashi","year":"2013","unstructured":"Kurahashi H, Watanabe M, Sugimoto M, Ariyoshi Y, Mahmood S, Araki M, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. Endocr J. 2013;60:1321\u20137.","journal-title":"Endocr J"},{"key":"47_CR32","doi-asserted-by":"publisher","first-page":"1219 e1217","DOI":"10.1016\/j.amjmed.2016.06.041","volume":"129","author":"YC Tung","year":"2016","unstructured":"Tung YC, Lee SS, Tsai WC, Lin GT, Chang HW, Tu HP. Association between gout and incident type 2 diabetes mellitus: a retrospective cohort study. Am J Med. 2016;129:1219 e1217\u201325.","journal-title":"Am J Med"},{"key":"47_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70:422\u201339.","journal-title":"Am J Kidney Dis"},{"key":"47_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"key":"47_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MOU.0b013e32835abd4a","volume":"23","author":"Y Bostanci","year":"2013","unstructured":"Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013;23:5\u201310.","journal-title":"Curr Opin Urol"},{"key":"47_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"G Gandaglia","year":"2013","unstructured":"Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432\u201341.","journal-title":"BJU Int"},{"key":"47_CR37","doi-asserted-by":"publisher","first-page":"e85588","DOI":"10.1371\/journal.pone.0085588","volume":"9","author":"SF Hung","year":"2014","unstructured":"Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS ONE. 2014;9:e85588.","journal-title":"PLoS ONE"},{"key":"47_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jsbmb.2015.08.007","volume":"154","author":"TM Kuo","year":"2015","unstructured":"Kuo TM, Yeh KT, Hsu HT, Chiang SL, Chang JG, Huang CM, et al. ALPK1 affects testosterone mediated regulation of proinflammatory cytokines production. J Steroid Biochem Mol Biol. 2015;154:150\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"47_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13075-015-0609-2","volume":"17","author":"TR Merriman","year":"2015","unstructured":"Merriman TR. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res Ther. 2015;17:98.","journal-title":"Arthritis Res Ther"},{"key":"47_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jmedgenet-2013-101518","volume":"50","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Nishida T, Ichihara S, Kato K, Fujimaki T, Oguri M, et al. Identification of chromosome 3q28 and ALPK1 as susceptibility loci for chronic kidney disease in Japanese individuals by a genome-wide association study. J Med Genet. 2013;50:410\u20138.","journal-title":"J Med Genet"},{"key":"47_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ije\/dyt028","volume":"42","author":"AM Ko","year":"2013","unstructured":"Ko AM, Tu HP, Liu TT, Chang JG, Yuo CY, Chiang SL, et al. ALPK1 genetic regulation and risk in relation to gout. Int J Epidemiol. 2013;42:466\u201374.","journal-title":"Int J Epidemiol"},{"key":"47_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3892\/br.2015.439","volume":"3","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Matsui K, Takeuchi I, Oguri M, Fujimaki T. Association of genetic variants of the alpha-kinase 1 gene with type 2 diabetes mellitus in a longitudinal population-based genetic epidemiological study. Biomed Rep. 2015;3:347\u201354.","journal-title":"Biomed Rep"},{"key":"47_CR43","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1210\/en.2009-0747","volume":"150","author":"SA Evans","year":"2009","unstructured":"Evans SA, Doblado M, Chi MM, Corbett JA, Moley KH. Facilitative glucose transporter 9 expression affects glucose sensing in pancreatic beta-cells. Endocrinology. 2009;150:5302\u201310.","journal-title":"Endocrinology"},{"key":"47_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ng.107","volume":"40","author":"A Doring","year":"2008","unstructured":"Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet. 2008;40:430\u20136.","journal-title":"Nat Genet"},{"key":"47_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/jhg.2016.57","volume":"61","author":"HP Tu","year":"2016","unstructured":"Tu HP, Chung CM, Min-Shan Ko A, Lee SS, Lai HM, Lee CH, et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet. 2016;61:803\u201310.","journal-title":"J Hum Genet"},{"key":"47_CR46","doi-asserted-by":"publisher","first-page":"527520","DOI":"10.1155\/2011\/527520","volume":"2011","author":"WC Liu","year":"2011","unstructured":"Liu WC, Hung CC, Chen SC, Lin MY, Chen LI, Hwang DY, et al. Thers1014290 polymorphism of the SLC2A9 gene is associated with type 2 diabetes mellitus in Han Chinese. Exp Diabetes Res. 2011;2011:527520.","journal-title":"Exp Diabetes Res"},{"key":"47_CR47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1136\/ard.2009.113357","volume":"69","author":"HP Tu","year":"2010","unstructured":"Tu HP, Chen CJ, Tovosia S, Ko AM, Lee CH, Ou TT, et al. Associations of a non-synonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders. Ann Rheum Dis. 2010;69:887\u201390.","journal-title":"Ann Rheum Dis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0047-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:11Z","timestamp":1684618391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0047-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0047-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"type":"print","value":"1365-7852"},{"type":"electronic","value":"1476-5608"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"2 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}